PROTHROMBIN G20210A
Clinical trials for PROTHROMBIN G20210A explained in plain language.
Never miss a new study
Get alerted when new PROTHROMBIN G20210A trials appear
Sign up with your email to follow new studies for PROTHROMBIN G20210A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to prevent dangerous clots in High-Risk patients
Disease control Recruiting nowThis early-stage study tests a single injection of CITY-FXI, a drug designed to lower clotting risk by targeting a protein called Factor XI. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to c…
Matched conditions: PROTHROMBIN G20210A
Phase: PHASE1 • Sponsor: City Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New study prepares those with genetic clot risk for future trials
Knowledge-focused Recruiting nowThis study enrolls 100 adults who have or may have Factor V Leiden or Prothrombin G20210A mutations, which increase the risk of blood clots. Participants undergo genetic testing to confirm their status, then attend a site visit for basic health checks like blood pressure, ECG, an…
Matched conditions: PROTHROMBIN G20210A
Sponsor: Richmond Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC